BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 17
• 18
• 19
• 20
• 21
• 22
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• Drug Development

  Akcea Initiates Phase II Study of AKCEA-ANGPTL3-LRx in Patients With Hypertriglyceridemia, Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease (NAFLD)

  The primary goal of the study is to determine the dose level and frequency for use of AKCEA-ANGPTL3-LRx in future registration studies.

  December 14, 2017

   · 

  5 min read
• Genetown

  HSS and pSivida Report Positive Phase I Knee Osteoarthritis Pain Study Data

  The implant was designed to deliver a continuous-low dose of dexamethasone into the knee joint for several months.

  December 14, 2017

   · 

  8 min read
• Galectin Therapeutics Provides Corporate Update at Annual Meeting

  The NASH-CX trial was a randomized, double-blind, placebo-controlled Phase 2b clinical trial which enrolled 162 NASH cirrhosis patients into the treatment phase.

  December 14, 2017

   · 

  7 min read
• Provecs Medical Announces Publication of Scientific Review of Gene Therapy in Oncology

  Provecs Medical GmbH, a cancer immunotherapy company developing novel treatments to modulate the tumor microenvironment, today announced the publication of a review highlighting the use of gene therapy approaches in immuno-oncology to address multiple targets with a single drug.

  December 14, 2017

   · 

  2 min read
• Drug Development

  Aura Biosciences Announces Publication of Preclinical Data Supporting AU-011’s Potent and Selective Anti-cancer Activity in Ocular Melanoma Tumors

  The data published today suggest that AU-011 may be further investigated as a novel first-line treatment option that can enable early intervention and potentially become the standard of care for patients with early-stage ocular melanoma.

  December 14, 2017

   · 

  4 min read
• Nexstim: Issuance of Shares Pursuant to the Restricted Share Unit Reward Plan

  The Company has today resolved on issuing altogether 9,910 new shares without payment to two members of the Board of Directors.

  December 14, 2017

   · 

  2 min read
• Business

  Creative Medical Technology Holdings Recruits Top Urologists for Caverstem™ Stem Cell Treatment of Erectile Dysfunction

  Creative Medical Technology announced today recruitment of leading urologists in the Southwestern United States to perform its patented Caverstem procedure to treat erectile dysfunction in patients who do not respond to currently available treatments.

  December 14, 2017

   · 

  2 min read
• MorphoSys to Present at Upcoming Investor Conferences

  MorphoSys will present at the following conferences.

  December 14, 2017

   · 

  3 min read
• Pharm Country

  ContraVir Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders Until December 21, 2017

  The record date for the Annual Meeting remains October 27, 2017. Stockholders who have previously submitted their proxy or otherwise voted and who do not want to change their vote need not take any action.

  December 14, 2017

   · 

  4 min read
• Drug Development

  AveXis Announces Plan to Initiate Phase I Trial in SMA Type II Utilizing Intrathecal Delivery of AVXS-101

  The company plans to initiate this trial immediately.

  December 14, 2017

   · 

  10 min read